Skip to content
lifestyle.thedailyhaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Satellos Bioscience Inc.
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
November 6, 2026
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
November 5, 2026
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
October 27, 2026
Satellos to Participate in Upcoming Investor Conferences
October 21, 2026
Satellos Granted Composition of Matter Patent for Forazapadin
October 5, 2026
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
September 30, 2026
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
September 24, 2026
Satellos to Present at the 31st Annual Congress of the World Muscle Society
September 15, 2026
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
September 9, 2026
Satellos to Participate in Upcoming Investor Conferences
September 1, 2026
1
2
Next Page
→